73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
Novel therapeutic targets discovered for triple-negative breast cancer

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of
FAM3C encapsulated in circulating tumor-derived extracellular vesicles promotes distant growth in lung cancers

FAM3C encapsulated in circulating tumor-derived extracellular vesicles promotes distant growth in lung cancers

byNational University of SingaporeTumor-derived EVs containing FAM3C trigger aggressiveness of lung carcinoma cells in vivo. (A) Tail vein injection of A549 lung carcinoma cells in mouse model a

FAM3C encapsulated in circulating tumor-derived extracellular vesicles promotes distant growth in lung cancers

byNational University of SingaporeTumor-derived EVs containing FAM3C trigger aggressiveness of lung carcinoma cells in vivo. (A) Tail vein injection of A549 lung carcinoma cells in mouse model a
New cell-based immunotherapy offered for melanoma

New cell-based immunotherapy offered for melanoma

by Julia Evangelou Strait,Washington University School of Medicine in St. LouisCredit: Pixabay/CC0 Public DomainSiteman Cancer Center, based at Barnes-Jewish Hospital and Washington University S

New cell-based immunotherapy offered for melanoma

by Julia Evangelou Strait,Washington University School of Medicine in St. LouisCredit: Pixabay/CC0 Public DomainSiteman Cancer Center, based at Barnes-Jewish Hospital and Washington University S
Why don't T cells destroy solid tumors during immunotherapy?

Why don't T cells destroy solid tumors during immunotherapy?

byUniversity of North Carolina Health Care3-D image of a T cell experiencing cell stress: endoplasmic reticulum (green), mitochondria (purple). Credit: Elizabeth Hunt, UNC School of MedicineThe

Why don't T cells destroy solid tumors during immunotherapy?

byUniversity of North Carolina Health Care3-D image of a T cell experiencing cell stress: endoplasmic reticulum (green), mitochondria (purple). Credit: Elizabeth Hunt, UNC School of MedicineThe
Can the flu shot help fight cancer?

Can the flu shot help fight cancer?

byRush University Medical CenterCredit: CC0 Public DomainChanging the microenvironment of tumors to increase the immune system's response to them has been the goal of countless research and

Can the flu shot help fight cancer?

byRush University Medical CenterCredit: CC0 Public DomainChanging the microenvironment of tumors to increase the immune system's response to them has been the goal of countless research and
UC San Diego Moores administers its first personalized cancer vaccine

UC San Diego Moores administers its first personalized cancer vaccine

by Paul Sisson, The San Diego Union-TribuneCredit: Min Yu (Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC),USC Norris Comprehensive Cancer CenterMore than 18 round

UC San Diego Moores administers its first personalized cancer vaccine

by Paul Sisson, The San Diego Union-TribuneCredit: Min Yu (Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC),USC Norris Comprehensive Cancer CenterMore than 18 round
AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate
Using machine learning to identify undiagnosable cancers

Using machine learning to identify undiagnosable cancers

by Bendta Schroeder,Massachusetts Institute of Technology“Machine learning tools like this one could empower oncologists to choose more effective treatments and give more guidance to their patie

Using machine learning to identify undiagnosable cancers

by Bendta Schroeder,Massachusetts Institute of Technology“Machine learning tools like this one could empower oncologists to choose more effective treatments and give more guidance to their patie
Tracking genes to fight breast cancer

Tracking genes to fight breast cancer

byLeiden UniversityMicroscope image of moving breast cancer cells leaving a track. Koedoot: "We switched of certain proteins and then looked to see if the pathways changed." Credit: Es

Tracking genes to fight breast cancer

byLeiden UniversityMicroscope image of moving breast cancer cells leaving a track. Koedoot: "We switched of certain proteins and then looked to see if the pathways changed." Credit: Es
Seeking leukemia's Achilles heel

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h
Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa